Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

  • Awaiting development
  • GID-TA11558
  • Expected publication date: TBC

30385-Niraparib-Abiraterone-Acetate-Prednisone-for-Prostate-Cancer-V1.0-APR2024-NON-CONF.pdf (nihr.ac.uk)